Amphotericin B loaded nanoemulsion: Optimization, characterization and in-vitro activity against L. donovani promastigotes.

Prajapat, VM; Aalhate, M; Sriram, A; Mahajan, S; Maji, I; Gupta, U; Kumari, D; Singh, K; Kalia, NP; Dua, K; Singh, SK; Singh, PK

Amphotericin B loaded nanoemulsion: Optimization, characterization and in-vitro activity against L. donovani promastigotes.

Prajapat, VM Aalhate, M Sriram, A Mahajan, S Maji, I Gupta, U Kumari, D Singh, K Kalia, NP Dua, K

Singh, SK Singh, PK

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Parasitol Int, 2023, pp. 102848
Issue Date:: 2023-12-28

Closed Access

	Filename	Description	Size
	Amphotericin B loaded nanoemulsion_L. donovani promastigotes .pdf	Published version	4.44 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Prajapat, VM
dc.contributor.author	Aalhate, M
dc.contributor.author	Sriram, A
dc.contributor.author	Mahajan, S
dc.contributor.author	Maji, I
dc.contributor.author	Gupta, U
dc.contributor.author	Kumari, D
dc.contributor.author	Singh, K
dc.contributor.author	Kalia, NP
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Singh, SK
dc.contributor.author	Singh, PK
dc.date.accessioned	2024-01-04T02:56:38Z
dc.date.available	2023-12-21
dc.date.available	2024-01-04T02:56:38Z
dc.date.issued	2023-12-28
dc.identifier.citation	Parasitol Int, 2023, pp. 102848
dc.identifier.issn	1383-5769
dc.identifier.issn	1873-0329
dc.identifier.uri	http://hdl.handle.net/10453/173985
dc.description.abstract	The present work aimed to develop and evaluate AmB-loaded nano-emulsion (AmB-NE) which will augment the solubility of AmB and lead to enhanced anti-leishmanial activity. The composition of AmB-NE was optimized by systematic screening followed by DoE-extreme vertices mixture design. The optimized NE revealed mean droplet size and PDI of 44.19 ± 5.5 nm, 0.265 ± 0.0723, respectively. The NE could efficiently encapsulate AmB with drug content and efficiency 83.509 ± 0.369% and 81.659 ± 0.013%, respectively. The presence of cholesterol and STE retarded the release (P < 0.0001) of AmB significantly compared to AmB suspension. The AmB-NE and pure AmB suspension demonstrated the IC50 of 0.06309 μg/mL and 0.3309 μg/mL against L. donovani promastigotes after 48 h incubation. The formulation was robust at all exaggerated stability conditions such as freeze-thaw and centrifugation. These findings indicate that AmB-NE is an attractive approach to treat visceral leishmaniasis with improved activity.
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	Parasitol Int
dc.relation.isbasedon	10.1016/j.parint.2023.102848
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0605 Microbiology, 0707 Veterinary Sciences, 1108 Medical Microbiology
dc.subject.classification	Mycology & Parasitology
dc.subject.classification	3009 Veterinary sciences
dc.subject.classification	3107 Microbiology
dc.title	Amphotericin B loaded nanoemulsion: Optimization, characterization and in-vitro activity against L. donovani promastigotes.
dc.type	Journal Article
utslib.location.activity	Netherlands
utslib.for	0605 Microbiology
utslib.for	0707 Veterinary Sciences
utslib.for	1108 Medical Microbiology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2024-01-04T02:56:29Z
pubs.publication-status	Published online

Abstract:

The present work aimed to develop and evaluate AmB-loaded nano-emulsion (AmB-NE) which will augment the solubility of AmB and lead to enhanced anti-leishmanial activity. The composition of AmB-NE was optimized by systematic screening followed by DoE-extreme vertices mixture design. The optimized NE revealed mean droplet size and PDI of 44.19 ± 5.5 nm, 0.265 ± 0.0723, respectively. The NE could efficiently encapsulate AmB with drug content and efficiency 83.509 ± 0.369% and 81.659 ± 0.013%, respectively. The presence of cholesterol and STE retarded the release (P < 0.0001) of AmB significantly compared to AmB suspension. The AmB-NE and pure AmB suspension demonstrated the IC50 of 0.06309 μg/mL and 0.3309 μg/mL against L. donovani promastigotes after 48 h incubation. The formulation was robust at all exaggerated stability conditions such as freeze-thaw and centrifugation. These findings indicate that AmB-NE is an attractive approach to treat visceral leishmaniasis with improved activity.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/173985